Lyra Therapeutics, Inc.
LYRA
Amendment
Ownership
15.55%
Total Shares
255,750
Issuer CIK
1327273
CUSIP
55234L105
Event Date
Aug 11, 2025
Accepted
Aug 14, 2025, 05:21 PM
SEC EDGARView Original Filing
Reporting Persons (4)
Joint Filing
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 15.55% | 255,750 | 0 | 255,750 |
| Joseph Edelman | Individual | 15.55% | 255,750 | 0 | 255,750 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 13.99% | 229,982 | 0 | 229,982 |
| Perceptive LS (A), LLC | CO | 1.57% | 25,768 | 0 | 25,768 |
Disclosure Items (2)
Security Title
Common Stock, $0.001 par value
Issuer Name
Lyra Therapeutics, Inc.
Issuer Address
480 Arsenal Way, Watertown, MA, 02472
Percentage of Class
The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,644,454 outstanding shares of Common Stock as of August 8, 2025 as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025.
Number of Shares
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.